Concienciación
Conozca más sobre los esfuerzos de defensa de la Asociación para garantizar el acceso de los pacientes a las terapias.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sep 15, 2020
Proposals for revision of donor deferral criteria in the context of the COVID-19 situation in order to maintain access to plasma-derived medicinal products for patients in EU
Proposals for revision of donor deferral criteria in the context of the COVID-19 situation in order to maintain access to plasma-derived medicinal products for patients in EU
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64522eeace0c39bce531cdfd_%2315EMA20011a_IPFA-PPTA_letter_to_EMA_Donor_acceptance_Criteria15SEP2020_Final.pdf
Sep 15, 2020
Proposals for revision of donor deferral criteria in the context of the COVID-19 situation in order to maintain access to plasma-derived medicinal products for patients in EU
Proposals for revision of donor deferral criteria in the context of the COVID-19 situation in order to maintain access to plasma-derived medicinal products for patients in EU
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64522eeace0c39bce531cdfd_%2315EMA20011a_IPFA-PPTA_letter_to_EMA_Donor_acceptance_Criteria15SEP2020_Final.pdf
Aug 4, 2020
Proposed Urgent Regulatory Actions to Increase Source Plasma Collections
On behalf of the Plasma Protein Therapeutics Association (PPTA), we wish to commend the Department’s efforts to increase collections of convalescent plasma as a treatment for patients diagnosed with COVID-19.
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64522f013303ce0a7b412d57_%2343-PPTA_Letter_to_HHS_Secretary_Azar_FINAL_08.04.2020.pdf
Aug 4, 2020
Proposed Urgent Regulatory Actions to Increase Source Plasma Collections
On behalf of the Plasma Protein Therapeutics Association (PPTA), we wish to commend the Department’s efforts to increase collections of convalescent plasma as a treatment for patients diagnosed with COVID-19.
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64522f013303ce0a7b412d57_%2343-PPTA_Letter_to_HHS_Secretary_Azar_FINAL_08.04.2020.pdf
May 1, 2020
Physicians in European Plasma Collection Centers
Many European countries have regulatory systems, which require the presence of a physician at all times in plasma collection centers.
All
Advocacy
https://plasmaprotein.sharepoint.com/:b:/s/EU/EUlhH2KT7FtCh5puxKTq7oQB2LUBty3vutdZqorv3FK8_w?e=lQ7y56
May 1, 2020
Physicians in European Plasma Collection Centers
Many European countries have regulatory systems, which require the presence of a physician at all times in plasma collection centers.
All
Advocacy
https://plasmaprotein.sharepoint.com/:b:/s/EU/EUlhH2KT7FtCh5puxKTq7oQB2LUBty3vutdZqorv3FK8_w?e=lQ7y56
Dec 20, 2018
International Pricing Index Model for Medicare Part B Comments
The Plasma Protein Therapeutics Association (PPTA) is pleased to comment on the Advance Notice of Proposed Rulemaking regarding the International Pricing Index Model (Model) for Medicare Part B Drugs.1 PPTA is the standard setting and global advocacy organization that represents plasma donation centers and manufacturers of plasma protein therapies.
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6453fa1e482b183f5309ec39_PPTA%20Comments%20on%20the%20International%20Pricing%20Index%20Model%20for%20Medicare%20Part%20B%20Drugs.pdf
Dec 20, 2018
International Pricing Index Model for Medicare Part B Comments
The Plasma Protein Therapeutics Association (PPTA) is pleased to comment on the Advance Notice of Proposed Rulemaking regarding the International Pricing Index Model (Model) for Medicare Part B Drugs.1 PPTA is the standard setting and global advocacy organization that represents plasma donation centers and manufacturers of plasma protein therapies.
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6453fa1e482b183f5309ec39_PPTA%20Comments%20on%20the%20International%20Pricing%20Index%20Model%20for%20Medicare%20Part%20B%20Drugs.pdf
No results found